HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TGTX
TG Therapeutics, Inc.
TGTX's fundamentals are strong, but it looks expensive: trading at 98x earnings, more than twice its usual 39x. Its downside scenario is about six times its upside.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TGTX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
TGTX's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TGTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 12x | $7.91 | -88% |
| Forward | 26x | $64.56 | — |
| Fair | 39x | $25.80 | -60% |
| Current | 98x | $64.56 | — |
| Expensive | 148x | $97.38 | +51% |
Historical ranges are pointers, not guarantees.
TGTX's PE is in its expensive range at 98x. If earnings grow as analysts expect, today's price would be 26x next year's earnings, in its fair range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TGTX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
TGTX has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TGTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.52 | +282% |
| Q3 2026 | $0.66 | -76% |
| Q2 2026 | $2.74 | +621% |
| Q1 2026 | $2.86 | +1044% |
| Q4 2025 | $2.77 | +1747% |
| Q3 2025 | $2.79 | +$2.89 |
| Q2 2025 | $0.38 | -38% |
| Q1 2025 | $0.25 | +8.7% |
| Q4 2024 | $0.15 | +650% |
TGTX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TGTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $259.9M | +61% |
| Q2 2026 | $240.3M | +70% |
| Q1 2026 | $204.9M | +70% |
| Q4 2025 | $192.6M | +78% |
| Q3 2025 | $161.7M | +93% |
| Q2 2025 | $141.1M | +92% |
| Q1 2025 | $120.9M | +90% |
| Q4 2024 | $108.2M | +146% |
TGTX has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 33% | +15 points |
| Q2 2026 | 9% | -16 points |
| Q1 2026 | 17% | +9.9 points |
| Q4 2025 | 26% | -1.5 points |
| Q3 2025 | 18% | +3.3 points |
| Q2 2025 | 25% | +13 points |
| Q1 2025 | 7.1% | +22 points |
| Q4 2024 | 28% | +56 points |
TGTX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
TGTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $44.9M | +$68.2M |
| Q2 2026 | $39M | +427% |
| Q1 2026 | -$17.9M | +$10.8M |
| Q4 2025 | $19.6M | +$45.3M |
| Q2 2025 | $7.4M | +34% |
| Q1 2025 | -$28.7M | -$20.5M |
| Q4 2024 | -$25.7M | -$12.5M |
| Q4 2023 | -$13.2M | +$10.7M |
TGTX has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TGTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TGTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -1.4M shares |
| 1 year | -3.2% | -5.1M shares |
| 3 years | 0% | +53.3K shares |
| 5 years | +18% | +23.6M shares |
| Available history | +76% | +67.6M shares |
TGTX has 156M diluted shares, down 3.2% from a year ago, with $200M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100M |
| Q2 2026 | — |
| Q1 2026 | $100M |
| Q4 2025 | — |
| Q3 2025 | $78.2M |
| Q2 2025 | $6.9M |
| Q1 2025 | $6.1M |
| Q4 2024 | $6.6M |
TGTX spent $200M buying back its own shares over the past year, up 104% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TGTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.9x | Healthy |
| Q1 2026 | 2.0x | Moderate |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.5x | Healthy |
TGTX's net debt is about 1.6 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TGTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 86.3 | Overbought |
TGTX's weekly RSI is 69 (neutral) and its Stochastic is 86 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TGTX PE vs Healthcare Sector
| Metric | TGTX | Sector median | Relative |
|---|---|---|---|
| PE | 98x | 26x | 278% above |
| PE % | 75 | 29 | 46 pts above |
TGTX is trading at 98x earnings, a 278% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TGTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $57.6 | 12% above |
| 20 week MA | $55.4 | 17% above |
| 50 week MA | $43.0 | 50% above |
| 100 week MA | $38.7 | 67% above |
| 200 week MA | $28.6 | 126% above |
TGTX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TGTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.9 | $53.3 | +390% |
| 2021 | $53.3 | $19.4 | -64% |
| 2022 | $19.4 | $8.12 | -58% |
| 2023 | $8.12 | $17.1 | +110% |
| 2024 | $17.1 | $32.5 | +90% |
| 2025 | $32.5 | $30.8 | -5.4% |
| 2026 YTD | $30.8 | $64.6 | +110% |
TGTX has the edge over HIMS on returns for 2026, with the stronger performance.